Sublingual Allergen-Specific Immunotherapy Adjuvanted with Monophosphoryl Lipid A: A Phase I/IIa Study | Zendy

Oliver Pfaar | Zendy; Christine Barth | Zendy; Christine Jaschke | Zendy; Karl Hörmann | Zendy; Ludger Klimek | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Sublingual Allergen-Specific Immunotherapy Adjuvanted with Monophosphoryl Lipid A: A Phase I/IIa Study

Author(s) -

Oliver Pfaar,

Christine Barth,

Christine Jaschke,

Karl Hörmann,

Ludger Klimek

Publication year - 2010

Publication title -

international archives of allergy and immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.696

H-Index - 100

eISSN - 1423-0097

pISSN - 1018-2438

DOI - 10.1159/000321826

Subject(s) - slit , medicine , tolerability , placebo , adverse effect , immunoglobulin e , immunology , allergy , sublingual administration , dosing , immunotherapy , gastroenterology , antibody , pharmacology , immune system , pathology , biology , genetics , alternative medicine

Sublingual immunotherapy (SLIT) allergy vaccines have an excellent safety profile, but opinions vary on their efficacy, and treatment regimens are often lengthy. This study assessed the effects of the Toll-like receptor 4 agonist monophosphoryl lipid A (MPL®) on safety/tolerability and clinical and immunological efficacy when combined with grass pollen SLIT formulations in treating patients with seasonal allergic rhinitis. This is the first reported study of adjuvanted SLIT.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research